【TASLY天士力是哪个国家的品牌？】

天士力集团是以大健康产业为主线，以生物医药产业为核心，以保健品、功能食品等健康产业以及健康管理与服务业为两翼的高科技跨国企业集团。

天士力集团1994年成立，始终秉承“追求天人合一，提高生命质量”的企业理念，坚持打造现代中药第一品牌，不断推进大健康产业持续快速发展。 

天士力以现代中药奠基立业，立足于现代科技创新，以组分中药为主导，形成了组分中药产业化开发的技术平台和先进制造平台。大力推进标准化管理的创新和系统化建设，形成了一条将药物研发、药材种植、中药提取、制剂生产和市场营销各环节集于一体的现代中药产业链，开发培育了一批疗效确切、市场信誉度高的现代中药产品群，其中最具代表的复方丹参滴丸2010年顺利通过了美国FDAⅡ期临床试验。

天士力研究院下设现代中药研究所、化学药物研究所、生物药品研究所、药理毒理研究所、药物分析研究所、食品与保健品研究所、国际法规与注册研究中心、国际法规与注册研究中心、药政事务管理中心、临床医学部、项目管理部以及办公室、物流与设备管理、科研财务等研发管理和服务保障部门。

天士力研究院现有管理和技术人员130人，其中博士及在站博士后22人、硕士38人，中、高级专业技术职称人员占研究院总人数的65%。

截止2006年底，天士力研究院先后承担国家级课题20项：其中九五攻关课题2项，十五攻关课题6项，863计划项目3项，产业化示范工程项目2项，参与国家973课题2项，以及其它国家级课题7项；获得受理的发明专利235件，获得授权的发明专利11件；获批16个新药生产批件、7个保健食品生产批件、40个新药临床批件。

在“没有围墙的研究院”的发展理念下，通过对科研资源的优化、整合和合理布局，研究院正在逐步打造药物合成、制剂、分析、药理筛选、临床、国内外注册等研究平台及项目管理平台。通过研究平台和管理平台的建设，适时地为创新型企业的可持续发展创造出有价值的创新产品。

复方丹参滴丸及其系列研究先后被国家科技部列入“中药现代科技产业行动计划”重中之重项目、九五国家重大科技成果推广项目、国家973基础研究项目和国家高新技术产业示范工程项目，并荣获国家科学技术进步三等奖。天士力技术中心被批准为国家级企业技术中心，国家人事部在天士力设立了企业博士后科研工作站。集团先后被评为“国家精神文明建设工作先进单位”、“天津市优秀企业”；“以中药现代化为目标的管理”荣获第八届国家企业管理现代化创新成果一等奖；天士力商标被国家工商局认定为“驰名商标”。

天士力集团被国家科学技术部、国务院国资委、中华全国总工会认定为“首批创新型企业”。天士力现代中药产业园作为国家高新技术产业化示范工程项目，2008年获得国家高技术产业化十年成就奖。天士力连续多年被评为“天津市优秀企业”、“天津市AAA劳动关系和谐企业”，连续两年被国家评为“全国精神文明建设先进单位”、“全国创建学习型组织先进单位”等荣誉称号。

近年来，特色化学药和高端生物药也获得快速发展。与英国COOP集团合资兴建的面向国际市场的化学药生产基地，已经实现生产出口。生物药以溶栓制剂尿激酶原和亚单位流感疫苗为龙头，形成了治疗用药与预防用药相结合的研发平台和产业平台。

借助于生物医药领域的技术优势，紧密结合食品、饮品等生活核心要素，向生命健康产业扩展。经过近年来的精心打造，形成了以“国台”为品牌的现代白酒产供销体系；“帝泊洱”生物茶、饮用水以及保健品、功能食品等产业领域，以科技创新为先导，以优势资源开发为基础，形成了规模化产能和品牌化营销。

面向未来，天士力集团将继续发展壮大“一个核心带两翼”的大健康产业格局，为实现“创造健康，人人共享”的目标，锐意创新，科学发展。

英文翻译：Tianshili group is a high-tech multinational enterprise group, which takes big health industry as the main line, biomedical industry as the core, health care products, functional food and other health industries as well as health management and service industry as the two wings. Founded in 1994, Tianshi group always adheres to the enterprise concept of "pursuing the unity of man and nature, improving the quality of life", adheres to building the first brand of modern Chinese medicine, and constantly promotes the sustainable and rapid development of large health industry. Based on modern scientific and technological innovation and guided by component traditional Chinese medicine, Tianshili has formed a technical platform and advanced manufacturing platform for the industrialization of component traditional Chinese medicine. Vigorously promote the innovation and systematic construction of standardized management, form a modern Chinese medicine industry chain integrating drug research and development, herbal medicine planting, Chinese medicine extraction, preparation production and marketing, develop and cultivate a number of modern Chinese medicine product groups with accurate curative effect and high market reputation, among which the most representative compound Danshen dropping pill successfully passed the FDA Ⅱ in 2010 Phase II clinical trial. The Institute consists of Institute of modern Chinese medicine, Institute of chemical medicine, Institute of biological medicine, Institute of pharmacology and toxicology, Institute of pharmaceutical analysis, Institute of food and health care products, international law and registration Research Center, international law and registration Research Center, drug administration management center, clinical medicine department, project management department and office, logistics and equipment management R & D management and service support departments such as scientific research finance. At present, there are 130 management and technical personnel in tisri, including 22 doctors, 38 postdoctors and 38 masters, and 65% of them have middle and senior professional and technical titles. By the end of 2006, tisri has successively undertaken 20 national level projects, including 2 in the ninth five year plan, 6 in the tenth five year plan, 3 in the 863 plan, 2 in the industrialization demonstration project, 2 in the national 973 project, and 7 in other national level projects, 235 accepted invention patents, 11 authorized invention patents, 16 new drug production approvals 7 health food production approvals and 40 new drug clinical approvals. Under the development concept of "research institutes without walls", through the optimization, integration and reasonable layout of scientific research resources, the research institutes are gradually building research platforms and project management platforms such as drug synthesis, preparation, analysis, pharmacological screening, clinical, registration at home and abroad. Through the construction of research platform and management platform, we can timely create valuable innovative products for the sustainable development of innovative enterprises. Compound Danshen dropping pill and its series of research have been listed as the top priority project of "action plan of modern science and technology industry of traditional Chinese medicine" by the Ministry of science and technology of the people's Republic of China, the promotion project of major scientific and technological achievements in the ninth five year plan, the National 973 basic research project and the national high and new technology industry demonstration project, and won the third prize of national science and technology progress. Tianshili technology center has been approved as a national enterprise technology center, and the Ministry of human resources has set up a postdoctoral research workstation in Tianshili. The group has been rated as "advanced unit of national spiritual civilization construction", "excellent enterprise of Tianjin", "management with modernization of traditional Chinese medicine as the goal" won the first prize of the eighth national enterprise management modernization innovation achievement, and the trademark of Tianshili has been recognized as "well-known trademark" by the State Administration of industry and commerce. Tianshili group is recognized as "the first batch of innovative enterprises" by the Ministry of science and technology, the state owned assets supervision and Administration Commission of the State Council and the all China Federation of trade unions. As a national high-tech industrialization demonstration project, tisley modern Chinese medicine industrial park won the national high-tech industrialization ten year achievement award in 2008. Tianshili has been awarded the titles of "excellent enterprise of Tianjin", "AAA harmonious enterprise of labor relations of Tianjin" for many consecutive years, and "advanced unit of national spiritual civilization construction", "advanced unit of national learning organization" for two consecutive years. In recent years, characteristic chemical drugs and high-end biological drugs have also achieved rapid development. The international market-oriented chemical drug production base jointly built with coop group in the UK has realized production and export. Biological drugs, led by thrombolytic agents urokinase and subunit influenza vaccine, have formed a research and development platform and industrial platform for the combination of therapeutic drugs and preventive drugs. With the help of the technical advantages in the field of biomedicine, and in close combination with the core elements of life such as food and drink, it will expand to the life and health industry. In recent years, a modern liquor production, supply and marketing system with "Guotai" as the brand has been formed; in the fields of bio tea, drinking water, health care products, functional food and other industries of "dipoer", guided by scientific and technological innovation and based on the development of advantageous resources, standardized production capacity and brand marketing have been formed. Facing the future, Tianshi group will continue to develop and expand the "one core with two wings" big health industry pattern, in order to achieve the goal of "creating health and sharing by everyone", it is committed to innovation and scientific development.

本文链接： https://www.waitui.com/brand/71be14c44.html 联系电话：022-26736812